Lucas J. Adams

Lucas J. Adams

Auto-generated profile, based on publicly available information

Lucas J. Adams

Department of Pathology & Immunology, Washington University School of Medicine, St Louis, MO, 63110, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Cell
Verified
Journal Article
Closed access
AHAhmed O. Hassan
Ahmed O. Hassan
NKNatasha M. Kafai
Natasha M. Kafai
IDIgor P. Dmitriev
Igor P. Dmitriev
JFJulie M. Fox
Julie M. Fox
BSBrittany K. Smith
Brittany K. Smith
MDMichael Diamond
Michael Diamond

1 September 2020 in Cell Host & Microbe
Verified
Journal Article
Closed access
JCJames Brett Case
James Brett Case
PRPaul W. Rothlauf
Paul W. Rothlauf
RCRita E. Chen
Rita E. Chen
NKNatasha M. Kafai
Natasha M. Kafai
JFJulie Fox
Julie Fox
MDMichael Diamond
Michael Diamond

1 July 2021 in Cell Reports
Verified
Journal Article
Open access
TBTraci L. Bricker
Traci L. Bricker
TDTamarand L. Darling
Tamarand L. Darling
AHAhmed O. Hassan
Ahmed O. Hassan
HHHouda H. Harastani
Houda H. Harastani
ASAllison Soung
Allison Soung
ABAdrianus C.M. Boon
Adrianus C.M. Boon
The development of an effective vaccine against SARS-CoV-2, the etiologic agent of COVID-19, is a global priority. Here, we compared the protective capacity of intranasal and intramuscular delivery of a chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike protein (ChAd-SARS-CoV-2-S) in Golden Syrian hamsters. While immunization with ChAd-SARS-CoV-2-S induced robust spike protein specific antibodies capable of neutralizing the virus, antibody levels in serum were higher in hamsters vaccinated by an intranasal compared to intramuscular route. Accordingly, against challenge with SARS-CoV-2, ChAd-SARS-CoV-2-S immunized hamsters were protected against less weight loss and had reduced viral infection in nasal swabs and lungs, and reduced pathology and inflammatory gene expression in the lungs, compared to ChAd-Control immunized hamsters. Intranasal immunization with ChAd-SARS-CoV-2-S provided superior protection against SARS-CoV-2 infection and inflammation in the upper respiratory tract. These findings support intranasal administration of the ChAd-SARS-CoV-2-S candidate vaccine to prevent SARS-CoV-2 infection, disease, and possibly transmission.

1 October 2021 in Immunity
Verified
Journal Article
Closed access
LVLaura A. VanBlargan
Laura A. VanBlargan
LALucas J. Adams
Lucas J. Adams
ZLZhuoming Liu
Zhuoming Liu
RCRita E. Chen
Rita E. Chen
PGPavlo Gilchuk
Pavlo Gilchuk
MDMichael Diamond
Michael Diamond

1 September 2019 in Cell Reports
Verified
Journal Article
Open access
RZRong Zhang
Rong Zhang
JEJames T. Earnest
James T. Earnest
AKArthur S. Kim
Arthur S. Kim
EWEmma S. Winkler
Emma S. Winkler
PDPritesh Desai
Pritesh Desai
MDMichael Diamond
Michael Diamond
Mxra8 is a recently described receptor for multiple alphaviruses, including Chikungunya (CHIKV), Mayaro (MAYV), Ross River (RRV), and O'nyong nyong (ONNV) viruses. To determine its role in pathogenesis, we generated mice with mutant Mxra8 alleles: an 8-nucleotide deletion that produces a truncated, soluble form (Mxra8Δ8/Δ8) and a 97-nucleotide deletion that abolishes Mxra8 expression (Mxra8Δ97/Δ97). Mxra8Δ8/Δ8 and Mxra8Δ97/Δ97 fibroblasts show reduced CHIKV infection in culture, and Mxra8Δ8/Δ8 and Mxra8Δ97/Δ97 mice have decreased infection of musculoskeletal tissues with CHIKV, MAYV, RRV, or ONNV. Less foot swelling is observed in CHIKV-infected Mxra8 mutant mice, which correlated with fewer infiltrating neutrophils and cytokines. A recombinant E2-D71A CHIKV with diminished binding to Mxra8 is attenuated in vivo in wild-type mice. Ectopic Mxra8 expression is sufficient to enhance CHIKV infection and lethality in transgenic flies. These studies establish a role for Mxra8 in the pathogenesis of multiple alphaviruses and suggest that targeting this protein may mitigate disease in humans.

17 May 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
SRSaravanan Raju
Saravanan Raju
LALucas J. Adams
Lucas J. Adams
JEJames T. Earnest
James T. Earnest
KWKelly Warfield
Kelly Warfield
LVLo Vang
Lo Vang
MDMichael Diamond
Michael Diamond
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes epidemics of acute and chronic musculoskeletal disease. Here, we analyzed the human B cell response to a CHIKV-like particle–adjuvanted vaccine (PXVX0317) from samples obtained from a phase 2 clinical trial in humans (NCT03483961). Immunization with PXVX0317 induced high levels of neutralizing antibody in serum against CHIKV and circulating antigen–specific B cells up to 6 months after immunization. Monoclonal antibodies (mAbs) generated from peripheral blood B cells of three PXVX0317-vaccinated individuals on day 57 after immunization potently neutralized CHIKV infection, and a subset of these inhibited multiple related arthritogenic alphaviruses. Epitope mapping and cryo–electron microscopy defined two broadly neutralizing mAbs that uniquely bind to the apex of the B domain of the E2 glycoprotein. These results demonstrate the inhibitory breadth and activity of the human B cell response induced by the PXVX0317 vaccine against CHIKV and potentially other related alphaviruses.